https://www.selleckchem.com/products/GDC-0449.html
Ensemble machine learning-based averaging of multiple pathway-extended models derived for an individual drug increased accuracy to 70% for erlotinib, gefitinib, lapatinib and sorafenib. Through incorporation of novel cancer biomarkers, machine learning-based pathway-extended signatures display strong efficacy predicting both sensitive and resistant patient responses to chemotherapy.Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease and highly resistant to all forms of therapy. PDAC cells reprogram their metabolism extensiv
Like
Comment
Share
